Docetaxel – Medxy AI

Docetaxel Rechallenge vs Cabazitaxel: Choosing the Right Taxane Sequence in Metastatic Castration-Resistant Prostate Cancer

By MedXY 02/09/2026

A retrospective cohort study of 669 veterans suggests that docetaxel rechallenge provides a significant survival benefit compared to cabazitaxel for patients with metastatic castration-resistant prostate cancer who previously responded to docetaxel without disease progression.

Clinical Updates news Oncology

Immunotherapy Challenges in Metastatic Castration-Resistant Prostate Cancer: An In-Depth Analysis of the CheckMate 7DX Phase 3 Trial

By MedXY 01/05/2026

CheckMate 7DX demonstrates that adding nivolumab to docetaxel fails to improve survival outcomes in ARPI-pretreated, chemotherapy-naive mCRPC, while significantly increasing toxicity and treatment-related mortality.

news Oncology Urology

Tailoring Systemic Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Evidence by Disease Volume and Timing of Metastasis

By MedXY 12/17/2025

A living network meta-analysis refines treatment strategies for mHSPC subgroups, favoring triplet therapy in synchronous high-volume cases and ARPI doublet therapy in others.

news Oncology Urology

Evolving Treatment Patterns and Survival Outcomes in Veterans With De Novo Metastatic Hormone-Sensitive Prostate Cancer

By MedXY 10/30/2025

A retrospective study in US veterans reveals increased use of combination therapies for metastatic hormone-sensitive prostate cancer (mHSPC), showing improved survival over ADT alone. ARPIs and docetaxel demonstrate comparable overall survival, with ARPIs providing longer progression-free survival.

news Oncology Specialties

Adagrasib vs Docetaxel in KRASG12C-Mutated NSCLC: New Hope from KRYSTAL-12 Phase 3 Trial

By MedXY 08/15/2025

The KRYSTAL-12 trial demonstrated that adagrasib significantly improves progression-free survival compared to docetaxel in previously treated KRASG12C-mutated advanced NSCLC, with manageable safety profiles.